Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors
Lin, N.-H., Xia, P., Kovar, P., Park, C., Chen, Z., Zhang, H., Rosenberg, S.H., Sham, H.L.(2006) Bioorg Med Chem Lett 16: 421-426
- PubMed: 16242328 
- DOI: https://doi.org/10.1016/j.bmcl.2005.09.064
- Primary Citation of Related Structures:  
2AYP - PubMed Abstract: 
Chk1 inhibitors have emerged as a novel class of neoplastic agents for abrogating the G2 DNA damage checkpoint arrest. Analogs of the Chk1 inhibitor, 3-ethylidene-1,3-dihydro-indol-2-one, were synthesized and tested in vitro for their inhibitory activities. The most promising compound identified from this series is analog 28, which possesses potent enzymatic and cellular activities.
Organizational Affiliation: 
Cancer Research, R-47B, Global Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-3500, USA. nanhorng.lin@abbott.com